ARTIVION INC (AORT)
US2289031005 - Common Stock
AORT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. AORT may be in some trouble as it scores bad on both profitability and health. AORT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
AORT had negative earnings in the past year.
AORT had a positive operating cash flow in the past year.
AORT had negative earnings in 4 of the past 5 years.
In multiple years AORT reported negative operating cash flow during the last 5 years.
1.2 Ratios
AORT has a better Return On Assets (-0.11%) than 69.89% of its industry peers.
AORT has a better Return On Equity (-0.28%) than 70.97% of its industry peers.
Looking at the Return On Invested Capital, with a value of 3.63%, AORT is in the better half of the industry, outperforming 74.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.11% | ||
| ROE | -0.28% | ||
| ROIC | 3.63% |
ROA(3y)-2.74%
ROA(5y)-2.01%
ROE(3y)-7.49%
ROE(5y)-5.38%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AORT's Operating Margin of 7.76% is fine compared to the rest of the industry. AORT outperforms 75.27% of its industry peers.
In the last couple of years the Operating Margin of AORT has declined.
AORT has a Gross Margin of 64.53%. This is in the better half of the industry: AORT outperforms 66.13% of its industry peers.
In the last couple of years the Gross Margin of AORT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.76% | ||
| PM (TTM) | N/A | ||
| GM | 64.53% |
OM growth 3Y10.94%
OM growth 5Y-6.03%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.77%
GM growth 5Y-0.33%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so AORT is destroying value.
The number of shares outstanding for AORT has been increased compared to 1 year ago.
Compared to 5 years ago, AORT has more shares outstanding
Compared to 1 year ago, AORT has an improved debt to assets ratio.
2.2 Solvency
AORT has an Altman-Z score of 2.13. This is not the best score and indicates that AORT is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.13, AORT is in the better half of the industry, outperforming 60.22% of the companies in the same industry.
The Debt to FCF ratio of AORT is 28.20, which is on the high side as it means it would take AORT, 28.20 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of AORT (28.20) is better than 68.82% of its industry peers.
A Debt/Equity ratio of 0.71 indicates that AORT is somewhat dependend on debt financing.
AORT has a Debt to Equity ratio of 0.71. This is in the lower half of the industry: AORT underperforms 69.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | 28.2 | ||
| Altman-Z | 2.13 |
ROIC/WACC0.4
WACC9.14%
2.3 Liquidity
AORT has a Current Ratio of 1.88. This is a normal value and indicates that AORT is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.88, AORT is not doing good in the industry: 69.35% of the companies in the same industry are doing better.
AORT has a Quick Ratio of 1.33. This is a normal value and indicates that AORT is financially healthy and should not expect problems in meeting its short term obligations.
AORT has a Quick ratio of 1.33. This is in the lower half of the industry: AORT underperforms 67.20% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.33 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 76.27% over the past year.
AORT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.29%.
The Revenue has been growing slightly by 6.14% on average over the past years.
EPS 1Y (TTM)76.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.17%
Revenue 1Y (TTM)13.29%
Revenue growth 3Y11.81%
Revenue growth 5Y6.14%
Sales Q2Q%9.02%
3.2 Future
Based on estimates for the next years, AORT will show a very strong growth in Earnings Per Share. The EPS will grow by 38.44% on average per year.
AORT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.95% yearly.
EPS Next Y101.15%
EPS Next 2Y48.01%
EPS Next 3Y38.44%
EPS Next 5YN/A
Revenue Next Year12.12%
Revenue Next 2Y10.93%
Revenue Next 3Y10.95%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AORT. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 197.60, the valuation of AORT can be described as expensive.
65.59% of the companies in the same industry are more expensive than AORT, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of AORT to the average of the S&P500 Index (23.69), we can say AORT is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 197.6 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AORT is valued a bit cheaper than the industry average as 73.66% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of AORT indicates a somewhat cheap valuation: AORT is cheaper than 68.82% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 103.93 | ||
| EV/EBITDA | 26.67 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AORT does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as AORT's earnings are expected to grow with 38.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.01%
EPS Next 3Y38.44%
5. Dividend
5.1 Amount
No dividends for AORT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ARTIVION INC
NYSE:AORT (1/3/2025, 8:20:01 PM)
After market: 27.88 0 (0%)27.88
-0.2 (-0.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners79.5%
Inst Owner ChangeN/A
Ins Owners5.51%
Ins Owner Change-2%
Market Cap1.17B
Analysts86.67
Price Target33.83 (21.34%)
Short Float %9.36%
Short Ratio14.35
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-43.76%
Min EPS beat(2)-110.11%
Max EPS beat(2)22.6%
EPS beat(4)3
Avg EPS beat(4)22%
Min EPS beat(4)-110.11%
Max EPS beat(4)168.88%
EPS beat(8)5
Avg EPS beat(8)-23.95%
EPS beat(12)8
Avg EPS beat(12)-59.33%
EPS beat(16)11
Avg EPS beat(16)10.21%
Revenue beat(2)0
Avg Revenue beat(2)-1.25%
Min Revenue beat(2)-1.6%
Max Revenue beat(2)-0.91%
Revenue beat(4)2
Avg Revenue beat(4)1.05%
Min Revenue beat(4)-1.6%
Max Revenue beat(4)3.85%
Revenue beat(8)5
Avg Revenue beat(8)1.16%
Revenue beat(12)8
Avg Revenue beat(12)0.94%
Revenue beat(16)11
Avg Revenue beat(16)7.7%
PT rev (1m)0%
PT rev (3m)9.39%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-276.2%
EPS NY rev (1m)-37.51%
EPS NY rev (3m)-86.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.44%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)0.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 197.6 | ||
| P/S | 3.04 | ||
| P/FCF | 103.93 | ||
| P/OCF | 50.96 | ||
| P/B | 3.84 | ||
| P/tB | N/A | ||
| EV/EBITDA | 26.67 |
EPS(TTM)-0.14
EYN/A
EPS(NY)0.14
Fwd EY0.51%
FCF(TTM)0.27
FCFY0.96%
OCF(TTM)0.55
OCFY1.96%
SpS9.18
BVpS7.27
TBVpS-2.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.11% | ||
| ROE | -0.28% | ||
| ROCE | 4.59% | ||
| ROIC | 3.63% | ||
| ROICexc | 3.97% | ||
| ROICexgc | 13.05% | ||
| OM | 7.76% | ||
| PM (TTM) | N/A | ||
| GM | 64.53% | ||
| FCFM | 2.92% |
ROA(3y)-2.74%
ROA(5y)-2.01%
ROE(3y)-7.49%
ROE(5y)-5.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y10.38%
ROICexcg growth 5Y-10.84%
ROICexc growth 3Y23.55%
ROICexc growth 5Y-6.28%
OM growth 3Y10.94%
OM growth 5Y-6.03%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.77%
GM growth 5Y-0.33%
F-Score6
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | 28.2 | ||
| Debt/EBITDA | 4.06 | ||
| Cap/Depr | 49.27% | ||
| Cap/Sales | 3.04% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 42.79% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.33 | ||
| Altman-Z | 2.13 |
F-Score6
WACC9.14%
ROIC/WACC0.4
Cap/Depr(3y)44.85%
Cap/Depr(5y)42.8%
Cap/Sales(3y)3.3%
Cap/Sales(5y)3.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.17%
EPS Next Y101.15%
EPS Next 2Y48.01%
EPS Next 3Y38.44%
EPS Next 5YN/A
Revenue 1Y (TTM)13.29%
Revenue growth 3Y11.81%
Revenue growth 5Y6.14%
Sales Q2Q%9.02%
Revenue Next Year12.12%
Revenue Next 2Y10.93%
Revenue Next 3Y10.95%
Revenue Next 5YN/A
EBIT growth 1Y170.38%
EBIT growth 3Y24.04%
EBIT growth 5Y-0.26%
EBIT Next Year1212.08%
EBIT Next 3Y162.09%
EBIT Next 5YN/A
FCF growth 1Y175.81%
FCF growth 3Y31.24%
FCF growth 5Y22.71%
OCF growth 1Y643.48%
OCF growth 3Y15.03%
OCF growth 5Y13.76%